Novo Nordisk | NVO - Equity Capital And Reserves


Novo Nordisk reported DKK26.56B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
Aurora Cannabis CAD 536.36M 30.74M Dec/2025
Bausch Health Companies USD -2.06B 1.5B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Canopy Growth CAD 758.17M 22.16M Dec/2025
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Drreddys Laboratories INR 4.14B 107.72M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Novo Nordisk DKK 26.56B 111.98B Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 1.89B 58.06M Mar/2026
Sanofi EUR 72.81B 1.1B Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026
Zoetis USD 3.23B 98M Mar/2026